OTLC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 19:37):

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications...

Stats
Dzisiejszy wolumen	5 064.00
Średni wolumen	70 993.00
Kapitalizacja rynkowa	15.75M
EPS	$0 ( 2024-04-12 )
Następna data zysków	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-29	Trieu Vuong	Buy	425 000	Common Stock
2023-06-28	Trieu Vuong	Buy	75 000	Common Stock
2023-06-16	Trieu Vuong	Buy	100 000	Common Stock
2023-06-14	Trieu Vuong	Buy	400 000	Common Stock
2023-05-26	Trieu Vuong	Buy	126 888	Common Stock

INSIDER POWER
100.00
Last 94 transactions
Buy: 129 604 070 \| Sell: 133 128 556

Oncotelic Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncotelic Therapeutics, Finanse

Annual	2023
Przychody:	$70 000.00
Zysk brutto:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2023
Przychody:	$70 000.00
Zysk brutto:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2022
Przychody:	$0
Zysk brutto:	$-12 841.00 (0.00 %)
EPS:	$0.0464

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Oncotelic Therapeutics,

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.